ArticleMolecular biotechnology2026
Promoter Methylation of WIF1 is Involved in IL-17-Induced Chondrocyte Inflammatory Injury and Matrix Degradation via Promoting Wnt5a/MAPK-JNK Signaling.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synovial Dysregulation in Ankle Osteoarthritis: Molecular Insights and Pathogenetic Pathways.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activity of Wnt inhibitory factor 1 (WIF1) is reduced upon promoter methylation and is involved in cartilage degradation in osteoarthritis. This study aims to investigate the mechanism by which WIF1 methylation is involved in chondrocyte damage in ankylosing spondylitis (AS). A model of chondrocyte inflammatory injury in AS was constructed by stimulation with interleukin (IL)-17. WIF1 level in injured chondrocytes was detected by western blot and RT-qPCR. ELISA kits were used to assess the levels of inflammatory cytokines. The expressions of MMP9, MMP13, collagen II, and ADAMTS-4 were tested by western blot and RT-qPCR. Wnt5a/mMAPK signaling and associated phosphorylated protein expressions were observed using western blot. After overexpression of Wnt5a, the same assays were used to evaluate the above indexes. The methylation level of the WIF1 promoter was measured by MSP-PCR assay. WIF1 expression declined in IL-17-induced chondrocytes. Overexpression of WIF1 decreased the levels of inflammatory factors TNFα, IL-1β, and IL-6, as well as downregulated the expressions of MMP9, MMP13, collagen II, and ADAMTS-4. Likewise, elevated WIF1 inhibited the Wnt5a/MAPK signaling and phosphorylation of JNK. However, upregulation of Wnt5a in IL-17-treated chondrocytes attenuated these responses. Besides, in damaged chondrocytes, WIF1 expression was reduced due to promoter methylation, while it was upregulated after demethylation. In summary, WIF1 exhibits high methylation levels in AS and is involved in inflammatory injury and matrix degradation in chondrocytes by regulating the Wnt5a/MAPK-JNK pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.